首页> 外文期刊>Radiation Oncology Journal >Postoperative radiotherapy appeared to improve the disease free survival rate of patients with extrahepatic bile duct cancer at high risk of loco-regional recurrence
【24h】

Postoperative radiotherapy appeared to improve the disease free survival rate of patients with extrahepatic bile duct cancer at high risk of loco-regional recurrence

机译:术后放疗似乎可以提高局部区域复发高风险的肝外胆管癌患者的无病生存率

获取原文
           

摘要

Purpose To investigate the outcomes of postoperative radiotherapy (RT), in patients with extrahepatic bile duct (EHBD) cancer by comparing the survival rate between patients undergoing surgery alone or surgery plus postoperative RT, and to identify the prognostic factors affecting survival. Materials and Methods Between 2000 and 2013, 52 patients with EHBD cancer underwent surgical resection. Of these, 33 patients did not receive postoperative RT (group I), and 19 patients did (group II). R1 resection was significantly more frequent in group II. The median radiation dose was 5,040 cGy. Results The 3-year overall survival (OS) rate for group I and group II was 38% and 56%, respectively (p = 0.274). The 3-year disease free survival (DFS) rate for group I and group II was 20% and 31%, respectively (p = 0.049), and the 3-year loco-regional recurrence free survival (LRFS) rates were 19% and 58%, respectively (p = 0.002). Multivariate analyses showed that postoperative RT and lymphovascular invasion were independent prognostic factors for DFS and LRFS. Overall, 42 patients (80%) experienced treatment failure. Distant metastasis was the predominant pattern of failure in group II. Conclusion Postoperative RT after surgical resection appeared to improve the loco-regional control and DFS rate. More effort is needed to reduce distant metastasis, the major pattern of failure, in patients who receive postoperative RT.
机译:目的通过比较单纯手术或手术加术后放疗的患者的生存率,研究肝外胆管癌(EHBD)患者的术后放疗(RT)的结果,并确定影响生存的预后因素。材料和方法2000年至2013年间,有52例EHBD癌症患者接受了手术切除。其中,33例未接受术后放疗(I组),19例未接受术后RT(II组)。在第二组中,R1切除术的频率明显更高。中值辐射剂量为5,040 cGy。结果I组和II组的3年总生存率分别为38%和56%(p = 0.274)。 I组和II组的3年无病生存率(DFS)分别为20%和31%(p = 0.049),3年局部无复发生存率(LRFS)为19%和分别为58%(p = 0.002)。多因素分析表明,术后RT和淋巴管浸润是DFS和LRFS的独立预后因素。总体而言,有42位患者(80%)经历了治疗失败。远处转移是第二组失败的主要模式。结论手术切除后术后放疗可改善局部区域控制和DFS率。接受术后放疗的患者需要付出更多的努力来减少远处转移,这是主要的失败方式。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号